E. Cohen
Boston University(US)
Publications by Year
Research Areas
Hepatitis C virus research, Liver Disease Diagnosis and Treatment, Hepatitis B Virus Studies, HIV/AIDS drug development and treatment, Systemic Lupus Erythematosus Research
Most-Cited Works
- → Efficacy of Direct-Acting Antiviral Combination for Patients With Hepatitis C Virus Genotype 1 Infection and Severe Renal Impairment or End-Stage Renal Disease(2016)277 cited
- → The Role of β Cell Glucagon-like Peptide-1 Signaling in Glucose Regulation and Response to Diabetes Drugs(2014)167 cited
- → Levels of Alanine Aminotransferase Confound Use of Transient Elastography to Diagnose Fibrosis in Patients With Chronic Hepatitis C Virus Infection(2012)102 cited
- → LO1 : Safety of ombitasvir/paritaprevir/ritonavir plus dasabuvir for treating HCV GT1 infection in patients with severe renal impairment or end-stage renal disease: The RUBY-I study(2015)74 cited
- → Prospective Randomized Study Comparing the Debriding Effect of Krill Enzymes and a Non-Enzymatic Treatment in Venous Leg Ulcers(1990)42 cited
- → Statins decrease TNF-α-induced osteoprotegerin production by endothelial cells and smooth muscle cells in vitro(2006)39 cited
- → Effect of Hepatitis C Treatment with Ombitasvir/Paritaprevir/R + Dasabuvir on Renal, Cardiovascular and Metabolic Extrahepatic Manifestations: A Post-Hoc Analysis of Phase 3 Clinical Trials(2017)30 cited
- → Ombitasvir/Paritaprevir/R, Dasabuvir, and Sofosbuvir Treatment of Patients with HCV Genotype-Infection who Failed a Prior Course of DAA Therapy: The Quartz-I Study(2016)27 cited
- → Efficacy and Safety of Ombitasvir/Paritaprevir/Ritonavir in Patients With Hepatitis C Virus Genotype 1 or 4 Infection and Advanced Kidney Disease(2018)25 cited
- → Safety of the 2D/3D direct-acting antiviral regimen in HCV-induced Child-Pugh A cirrhosis – A pooled analysis(2017)14 cited